Sha Zhu

机构：Jiangnan University, UMass Memorial Health Care, University of Massachusetts Chan Medical School, Hunan Normal University, University of California, San Francisco, Sichuan University, West China Hospital of Sichuan University, Wuxi No.2 People's Hospital, Hunan Children's Hospital, Second Affiliated Hospital of Zhejiang University, Nanjing Medical University · ORCID：0000-0003-1152-2536

发表论文 198 篇 · 总被引 2414 次 · h-index 25

代表论文

• The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis (2024 · Cancer Treatment Reviews · 被引 26)
• Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma (2024 · Molecular Cancer · 被引 18)
• Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets (2025 · Nature Communications · 被引 14)
• Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents (2025 · Modern Pathology · 被引 7)
• Medical and work loss costs of violence, self-harm, unintentional and traumatic brain injuries per injured person in the USA (2024 · Injury Prevention · 被引 6)
• UBE2D3 facilitates NHEJ by orchestrating ATM signalling through multi-level control of RNF168 (2024 · Nature Communications · 被引 6)